活化蛋白C对凝血因子VIII功能的调控作用
研究比较野生型无B域FVIII与APC抗性FVIII变体(FVIII-QQ),在血浆实验和血友病A小鼠模型中评估APC对FVIIIa的调控。结果显示FVIII-QQ在两种损伤模型中促凝功能较野生型增大约五倍,且该增强效应可被PC/APC抑制性抗体消除,表明APC在体内参与FVIIIa的调控。
要点
- APC通过切割FVIIIa在体内调控其辅因子功能
- APC抗性FVIII变体在血友病A小鼠中止血功能增强约五倍
- 该增强效应具APC特异性,可被PC/APC抑制性抗体消除
核心结论
- APC在体内对FVIIIa功能具有调控作用,此机制有望用于开发新型血友病A治疗策略。
研究设计与样本
- 对比野生型无B域FVIII重组蛋白与APC抗性FVIII变体(FVIII-R336Q/R562Q;FVIII-QQ)的体外及体内功能。
主要发现
- FVIII-QQ表现出预期的APC抗性,且促凝功能与A2域解离无其他改变。
- 在血浆实验中,FVIII-WT/FVIIIa-WT对APC呈剂量依赖性敏感(有无蛋白S均如此),而FVIII-QQ/FVIIIa-QQ不敏感。
- 在血友病A小鼠的尾夹伤和氯化铁损伤模型中,FVIII-QQ的促凝功能较FVIII-WT增大约五倍。
- 在纯合HA/FV Leiden小鼠尾夹伤实验中,FVIII-QQ仍显示增强的止血功能;但加入阻断小鼠PC/APC止血功能的单克隆抗体1609后,FVIII-QQ与FVIII-WT表现相似,表明FVIII-QQ的增强止血效应具APC特异性。
临床怎么用
- APC抗性FVIII变体可能作为增强止血功能的新型血友病A治疗候选分子。
局限性
- 研究主要基于小鼠模型和体外血浆实验,尚未在人体中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mechanisms thought to regulate activated factor VIII (FVIIIa) cofactor function include A2-domain dissociation and activated protein C (APC) cleavage. Unlike A2-domain dissociation, there is no known phenotype associated with altered APC cleavage of FVIII, and biochemical studies have suggested APC plays a marginal role in FVIIIa regulation. However, the in vivo contribution of FVIIIa inactivation by APC is unexplored. Here we compared wild-type B-domainless FVIII (FVIII-WT) recombinant protein with an APC-resistant FVIII variant (FVIII-R336Q/R562Q; FVIII-QQ). FVIII-QQ demonstrated expected APC resistance without other changes in procoagulant function or A2-domain dissociation. In plasma-based studies, FVIII-WT/FVIIIa-WT demonstrated dose-dependent sensitivity to APC with or without protein S, whereas FVIII-QQ/FVIIIa-QQ did not. Importantly, FVIII-QQ demonstrated approximately fivefold increased procoagulant function relative to FVIII-WT in the tail clip and ferric chloride injury models in hemophilia A (HA) mice. To minimize the contribution of FV inactivation by APC in vivo, a tail clip assay was performed in homozygous HA/FV Leiden (FVL) mice infused with FVIII-QQ or FVIII-WT in the presence or absence of monoclonal antibody 1609, an antibody that blocks murine PC/APC hemostatic function. FVIII-QQ again demonstrated enhanced hemostatic function in HA/FVL mice; however, FVIII-QQ and FVIII-WT performed analogously in the presence of the PC/APC inhibitory antibody, indicating the increased hemostatic effect of FVIII-QQ was APC specific. Our data demonstrate APC contributes to the in vivo regulation of FVIIIa, which has the potential to be exploited to develop novel HA therapeutics.
引用
- Wilhelm AR, Parsons NA, Samelson-Jones BJ, et al. Activated protein C has a regulatory role in factor VIII function. Blood. 2021. PMID: 33512448. doi:10.1182/blood.2020007562
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。